The FDA has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for people with severe asthma.

WASHINGTON - The Food and Drug Administration has approved Exdensur as an add-on maintenance treatment for patients aged 12 ...

Depemokimab-ulaa (Exdensur) is approved for severe asthma with an eosinophilic phenotype, offering protection with just two ...

If the FeNO level is not raised, it is recommended that the patient be offered either a Long-Acting Muscarinic Antagonist (LAMA) or a Leukotriene Receptor Antagonist (LTRA) on top of a moderate-dose ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Joshua M. Kosowsky ...

Why are we asking for donations? Why are we asking for donations? This site is free thanks to our community of supporters. Voluntary donations from readers like you keep our news accessible for ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Todd A. Florin, MD ...

Scientists have found a new treatment for people with asthma and chronic obstructive pulmonary disease (COPD) that may be more effective than current options. Over the past 50 years, treatment options ...

GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Exdensur ...

In the early 20 th century, asthma was thought of as a psychosomatic disease, which means that the illness was caused by psychological problems that lead to development of physical symptoms. At that ...

Vermont Business Magazine New research from the University of Vermont reveals exposure to smoke from Canadian wildfires in ...

The FDA has approved Exdensur for add-on maintenance treatment of severe asthma characterized by an eosinophilic phenotype in patients aged 12 and older.